Jazz Pharmaceuticals plc
NASDAQ:JAZZ 12:59:59 PM EDT
| Market Cap (Intraday) | 7.96B |
| Current PE | 198.29 |
| Forward PE | 8.91 |
| 2yr Forward PE | 7.4 |
| 10-Day MA | $133.18 |
| 50-Day MA | $150.33 |
| 200-Day MA | $163.10 |
Jazz Pharmaceuticals plc Stock, NASDAQ:JAZZ
Waterloo Exchange, Waterloo Road, Dublin, Dublin 4
Ireland
Phone: +353.1.634.7800
Number of Employees: 1940
Description
Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry. Its product portfolio includes: Xyrem, Xywav, Sunosi, Erwinaze, Vyxeos, Defitelio, and Zepzelca. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.